ArticleFrontiers in cellular and infection microbiology2022
Human umbilical cord mesenchymal stem cells regulate immunoglobulin a secretion and remodel the diversification of intestinal microbiota to improve colitis.
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Mesenchymal stem cell therapy and gut microbiota modulation in preclinical disease models: a systematic review with implications for hypertension.Molecular biology reports · 2026Pooled it
- Impact of Mesenchymal Stem Cells on the Gut Microbiota and Microbiota Associated Functions in Inflammatory Bowel Disease: A Systematic Review of Preclinical Evidence on Animal Models.Current stem cell research & therapy · 2024Pooled it
- Salidroside and mesenchymal stem cells alleviate hypobaric hypoxia-induced lung injury and are associated with alterations in the gut-lung axis.Biochemistry and biophysics reports · 2026Article
- Review
- Article
- Decoding the gut microbiota-immune dialogue: from bidirectional axis to therapeutic applications.Journal of nanobiotechnology · 2026Review
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
- Mesenchymal stem cells: a potential therapeutic strategy for IgA nephropathy.Frontiers in pharmacology · 2026Review
- Exploring the role of gut microbiota modulation in the long-term therapeutic benefits of early MSC transplantation in MRL/lpr mice.Cellular & molecular biology letters · 2025Article
- Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Nanovesicles Alleviated Colitis via Modulating Th17/Treg Balance Through Hsa-miR-27b-3p-Mediated Suppression of PI3K/AKT/STAT3 Signaling Pathway.International journal of nanomedicine · 2025Article
- IgG/IgM-coated gut microbiota in schizophrenia: associations with inflammation disease activity.Frontiers in psychiatry · 2025Article
- Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease.Inflammopharmacology · 2024Review
- Therapeutic Prospects of Mesenchymal Stem Cell and Their Derived Exosomes in the Regulation of the Gut Microbiota in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Mesenchymal Stromal Cells: New Generation Treatment of Inflammatory Bowel Disease.Journal of inflammation research · 2024Review
- Case report: Allogeneic feline umbilical cord-derived mesenchymal stem cell transplantation for feline oral squamous cell carcinoma.Frontiers in veterinary science · 2024Article
- Multiomics reveal human umbilical cord mesenchymal stem cells improving acute lung injuryWorld journal of stem cells · 2023Article
- Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis.Stem cell research & therapy · 2023Article
- Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.European journal of medical research · 2023Review
- Intestinal fungi and antifungal secretory immunoglobulin A in Crohn's disease.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mesenchymal stem cell (MSC) therapy has emerged as a promising novel therapeutic strategy for managing inflammatory bowel disease (IBD) mainly Methods: In the present study, dextran sulfate sodium (DSS) was used to induce colitis in mice. Mice with colitis were treated with intraperitoneal infusions of MSCs from human umbilical cord mesenchymal stem cells (HUMSCs) and evaluated for severity of inflammation including weight reduction, diarrhea, bloody stools, histopathology, and mortality. The proportion of regulatory T cells (Tregs) and immunoglobulin A-positive (IgA Results: Treatment with HUMSCs ameliorated the clinical abnormalities and histopathologic severity of acute colitis in mice. Furthermore, the proportion of Tregs in both Peyer's patches and lamina propria of the small intestine was significantly increased. Meanwhile, the proportion of IgA Conclusions: Therapeutically administered HUMSCs ameliorate DSS-induced colitis partially
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.